Pharmacology: Pharmacodynamics: Ambroxol HCl is a metabolite of bromhexine which is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. It alters the structure of mucus to decrease its viscosity, and therefore, facilitate its removal by ciliary action or expectoration.
Helps in clearing airway and control of chesty cough caused by excessive tenacious mucus.
Adults: Suck 2 lozenges, 3 times daily. Children 6-12 years: Suck 1 lozenge, 3 times daily. Do not exceed stated dose. If symptom persist, consult the doctor.
No symptoms of overdose have been reported in man to date. If they occur, symptomatic treatment should be provided.
Allergy or hypersensitivity to any of the ingredients of Strepsils.
Use in pregnancy & lactation: The usual precautions regarding the use of drugs during pregnancy, especially during the 1st trimester should be observed. During breastfeeding, it should be used only if necessary.
Use in children: Young children can choke on lozenges.
The usual precautions regarding the use of drugs during pregnancy, especially during the 1st trimester should be observed. During breastfeeding, it should be used only if necessary.
Strepsils Chesty Cough is generally well tolerated. However, mild upper gastrointestinal adverse reactions eg, mouth dryness, nausea, vomiting and diarrhoea have been reported. Allergic reactions have occurred rarely, primarily skin rashes and hypersensitivity.
Administration of ambroxol together with antibiotics (amoxicillin, cefuroxime, erythromycin, doxycycline) leads to higher antibiotic concentration in the lung tissue. No clinically relevant unfavourable interaction with other medications have been reported.
Store in a dry place, below 25°C.
Shelf-Life: 3 years.
R05CB06 - ambroxol ; Belongs to the class of mucolytics. Used in the treatment of wet cough.
Loz (orange-yellow, circular, with characteristic orange-odour) 15 mg x 24's.